Biotech | October 15, 2021
Exelixis in-licenses second anti-cancer compound from Aurigene
U.S. FDA has accepted the investigational new drug application for phase 1 clinical trial in non-Hodgkin’s lymphoma
U.S. FDA has accepted the investigational new drug application for phase 1 clinical trial in non-Hodgkin’s lymphoma
BDMP is a personalised program delivered through the Breathe app to assist people with Type 2 Diabetics to achieve healthy outcomes
Since its inception, the company has either acquired or taken a majority stake in five companies
_256_384.jpg)
The two doses of Covaxin are likely to be administered to children with a gap of 28 days
The test kit uses a reagent developed using Kaneka's molecular testing-related technologies
If authorized, molnupiravir could be the first oral antiviral medicine for the treatment of Covid-19
The company has enabled a transformation across three core areas with an investment target of US $ 150 million
The applicants will only have to get their Good Manufacturing Practices certification validated every five years to retain their licence
The rolling submission to the U.S. FDA will begin in the fourth quarter of this year
The agreement will sharpen Cigna's focus on the growth path for its rapidly expanding global health portfolio
Subscribe To Our Newsletter & Stay Updated
